Zocovas F 10mg/160mg Tablet is a combination medication containing Atorvastatin 10mg and Fenofibrate 160mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Atorvastatin, a selective HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and total cholesterol by inhibiting cholesterol synthesis in the liver. Fenofibrate, a fibric acid derivative, primarily lowers triglycerides and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), enhancing lipid metabolism. This dual-action formulation is particularly beneficial for patients with persistent lipid abnormalities despite monotherapy or those with combined hyperlipidemia requiring comprehensive lipid control. Zocovas F is administered orally, typically once daily, with or without food, under medical supervision. It is essential to monitor liver function tests, renal function, and lipid profiles periodically during treatment to assess efficacy and detect potential adverse effects. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. Common side effects may include gastrointestinal disturbances, myalgia, and elevated liver enzymes. Zocovas F should be used as part of a comprehensive cardiovascular risk reduction strategy, including diet, exercise, and lifestyle modification.